All
Novel Therapy in Combination With Opdivo Shows Promise for Lung Cancer Subset
January 29th 2021Treatment with Opdivo (nivolumab) in combination with the novel therapy BMS-986012 demonstrated a median overall survival of 18.7 months and a median progression-free survival of 2.1 months among a group of patients with relapsed/refractory small cell lung cancer.
Patients With Lung Cancer May Need More Support, Education When Making Treatment Decisions
January 29th 2021In a survey conducted by the Cancer Support Community, 33% of patients with lung cancer reported they were somewhat or not at all involved in the decision-making process, and 66% were not as knowledgeable about their treatment options as needed to make this decision.
How One Patient With Cancer is Paying it Forward From ‘Chemo to Kindness’
January 28th 2021In this episode of the “CURE Talks Cancer” podcast, we spoke with a patient who is receiving treatment for grade 3 triple-negative breast cancer. We talk about how a nurse’s question during a routine physical “saved her life”, and a kindness challenge she started to help lift her up during the dark days of treatment.
Avastin Plus Chemotherapy Improves Progression-Free and Overall Survival in Mucosal Melanoma
January 27th 2021Avastin, in combination with carboplatin plus paclitaxel (types of chemotherapy), improved progression-free survival and overall survival compared with those who received chemotherapy alone for patients with untreated advanced mucosal melanoma.
Aliqopa With Chemotherapy Did Not Improve Short-Term Progression-Free Survival
January 27th 2021In a phase 2 study of 24 patients with biliary cancer, Aliqopa in combination with Gemzar and chemotherapy led to a six-month progression-free survival rate of 51% with a median overall survival of 13.7 months.
Chemotherapy With Immunotherapy Improves Overall Survival for Extensive-Stage Small Cell Lung Cancer
January 27th 2021Tecentriq with carboplatin and etoposide led to a median overall survival rate of 12.3 months versus 10.3 months in those assigned placebo, carboplatin and etoposide, although the death rate was high at a median follow-up of 22.9 months.